When a positive culture speaks: lower respiratory Aspergillus isolation as a prognostic marker in invasive pulmonary aspergillosis
Article information
Invasive pulmonary aspergillosis (IPA) is a serious fungal infection caused by inhaled Aspergillus species [1,2]. Once regarded as a complication almost confined to profound neutropenia and hematologic malignancy, it is now seen, particularly at tertiary centers in Korea, across a much wider range of non-neutropenic hosts. These include the elderly, those with chronic airway or parenchymal lung disease, transplant recipients, patients on long-term corticosteroids, and those with severe viral pneumonia from COVID-19 or influenza [3]. Over the same period, non-culture biomarkers such as galactomannan (GM) and molecular assays have reshaped early diagnosis [4], and in bronchoalveolar lavage (BAL) fluid the GM assay offers useful diagnostic yield despite a recognized risk of false-positive results [5]. Against this backdrop, the meaning of isolating Aspergillus from a lower respiratory tract (LRT) specimen has remained contested. Some reports in transplant and critically ill cohorts have linked positive cultures to worse outcomes [6], while others have found no such association [7], in part because earlier studies grouped patients by survival rather than comparing culture-positive cases against a clearly defined culture-negative cohort. In an era increasingly led by rapid biomarkers, the study by Kim et al. [8] reminds us that the main value of a positive culture today may be prognostic rather than diagnostic.
A CULTURE-NEGATIVE CONTROL REVEALS A GENUINE PROGNOSTIC SIGNAL
Kim et al. asked whether a positive LRT culture carries prognostic information specifically among patients who already have proven or probable IPA. The strength of their design is the comparator: 50 culture-positive patients were set against 69 control patients who also met the 2020 EORTC/MSGERC criteria [4] but had negative fungal cultures on BAL. Because the underlying diagnosis was held constant in both arms, the comparison isolates the added value of the culture result itself rather than the effect of having IPA, and it avoids the survivor-based comparisons used before. After propensity-score weighting, culture-positive patients had higher 6-week mortality (48.3% vs. 29.8%; odds ratio [OR], 2.20; 95% confidence interval, 1.24–3.92), an association that held on adjusted analysis, with a consistent but weaker trend at 12 weeks.
A plausible reason for this excess mortality emerges from the microbiology and imaging. Culture-positive patients carried a heavier airway fungal burden, with a higher median BAL GM index (5.00 vs. 1.99) and more frequent high-grade radiologic findings [9], whereas serum galactomannan and the halo sign did not differ between groups. Because these signals were confined to the respiratory tract rather than the bloodstream, they support the idea that a positive culture reflects extensive local disease in the airways and lung tissue rather than greater angioinvasion.
A POSITIVE SPUTUM CULTURE DESERVES VIGILANCE, NOT DISMISSAL
The most practical message concerns the sputum culture. In routine care, a report of Aspergillus in sputum is often dismissed as colonization or contamination, which is a reasonable default in a healthy host. Within this cohort of established IPA, however, sputum culture positivity carried almost the same 6-week risk as BAL positivity (OR, 2.39 vs. 2.03). This should not be read as diagnostic equivalence, because every patient had undergone bronchoscopy and met strict criteria, so sputum cannot replace BAL in an undifferentiated case. Even so, the bedside message is plain: in a vulnerable host with compatible infiltrates, growing Aspergillus in sputum is not background noise but a red flag that deserves prompt attention.
ASSOCIATION, NOT CAUSATION
The exploratory subgroup analyses expose the ambiguity of everyday practice. The prognostic penalty of culture positivity was clearest in patients with hematologic malignancy or neutropenia and largely disappeared in those with lung cancer or chronic lung disease. These comparisons are underpowered, with small subgroups and non-significant interaction tests, but the divergence mirrors a familiar problem in Korea, where parenchymal destruction from prior tuberculosis, bronchiectasis, and chronic pulmonary aspergillosis is common. In such damaged lungs, Aspergillus may live saprophytically for years without invading [10], so a positive culture becomes far less specific. A more fundamental limitation is that propensity weighting balanced baseline comorbidity and immune status but could not capture acute physiological severity, such as mechanical ventilation, shock, organ failure, or delayed antifungal initiation. Because these acute factors drive much of early death, culture positivity may partly reflect how sick a patient already was rather than act as an independent cause, which is why the authors rightly read their mortality findings as associations rather than proof.
One caveat cuts across all of this. Because respiratory culture is insensitive, its prognostic value runs in a single direction: a positive result signals danger, but the 58% of this cohort with negative cultures still faced substantial mortality, so a negative culture can never offer reassurance.
FROM PROGNOSTIC MARKER TOWARD BETTER CARE
Advancing this field will require answering two unresolved questions. Clinically, culture remains uniquely valuable because it yields a viable organism for species identification and azole-resistance profiling, information that matters more as environmental azole resistance rises yet was unavailable in this retrospective series. Quantitative molecular tools such as Aspergillus PCR or microbial cell-free DNA might one day turn a positive result into a measure of fungal load. They are not yet routine in Korea, however, so for now conventional culture and galactomannan remain our main tools. More fundamentally, whether acting on a positive culture actually improves outcomes is still unknown, and settling it will require prospective, multicenter studies that tie culture results to specific management and then test whether that management helps.
The broader lesson of Kim et al. is not that we must choose between culture and biomarkers, since the two answer different questions. Galactomannan and molecular tests have earned their place at the diagnostic front line, but a positive culture speaks to how severe the disease already is and hands us the organism itself. Seen this way, respiratory culture is not a relic displaced by the biomarker era but a complement to it. A positive result should prompt a closer look at disease severity and host risk rather than a reflexive change in therapy, because a prognostic marker and a treatment decision are not the same, and antifungal stewardship still applies.
Notes
Conflicts of interest
The author discloses no conflicts.
Funding
None
